- Home
- IBG vs ATNF Comparison
IBG vs ATNF Comparison
Compare IBG & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- ATNF
- Stock Information
- Founded
- IBG 2018
- ATNF 2016
- Country
- IBG Australia
- ATNF United States
- Employees
- IBG N/A
- ATNF N/A
- Industry
- IBG Beverages (Production/Distribution)
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- ATNF Health Care
- Exchange
- IBG Nasdaq
- ATNF Nasdaq
- Market Cap
- IBG 4.1M
- ATNF 4.1M
- IPO Year
- IBG 2024
- ATNF N/A
- Fundamental
- Price
- IBG $0.72
- ATNF $0.88
- Analyst Decision
- IBG Strong Buy
- ATNF
- Analyst Count
- IBG 1
- ATNF 0
- Target Price
- IBG N/A
- ATNF N/A
- AVG Volume (30 Days)
- IBG 12.0M
- ATNF 135.9K
- Earning Date
- IBG 05-15-2025
- ATNF 05-14-2025
- Dividend Yield
- IBG N/A
- ATNF N/A
- EPS Growth
- IBG N/A
- ATNF N/A
- EPS
- IBG N/A
- ATNF N/A
- Revenue
- IBG $3,147,763.00
- ATNF N/A
- Revenue This Year
- IBG N/A
- ATNF N/A
- Revenue Next Year
- IBG N/A
- ATNF N/A
- P/E Ratio
- IBG N/A
- ATNF N/A
- Revenue Growth
- IBG N/A
- ATNF N/A
- 52 Week Low
- IBG $0.44
- ATNF $0.66
- 52 Week High
- IBG $3.35
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- IBG N/A
- ATNF 41.34
- Support Level
- IBG N/A
- ATNF $0.80
- Resistance Level
- IBG N/A
- ATNF $0.91
- Average True Range (ATR)
- IBG 0.00
- ATNF 0.11
- MACD
- IBG 0.00
- ATNF 0.02
- Stochastic Oscillator
- IBG 0.00
- ATNF 42.99
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.